Skip to content

Public FDA record

Z-3143-2024: Seer Home System is an ambulatory electroencephalograph (EEG) system intended for at-home use for extende

Recall record Z-3143-2024 for SEER MEDICAL PTY LTD. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-3143-2024
Company in FDA record
SEER MEDICAL PTY LTD
FDA classification date
Sep 13, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

During CAPA investigations of sight production inconsistencies, it was highlighted that previous Electromagnetic Compatibility (EMC) assessments related to RF radiated emissions may not be reasonably equivalent to the current product due to design changes in the system. A new CAPA was opened to investigate the radiated emissions compliance issues. - Seer Home Systems distributed and retained in the field were not compliant with Electromagnetic Compatibility (EMC) testing according to IEC 60601-1-2 - Seer Home Systems, including accessories, were manufactured and distributed without application of proper design change and manufacturing controls - Seer Home Systems were distributed with labeling deficiencies

Source facts

Action
Seer Medical notified consignees on 08/12/2024, via email. Consignees were instructed that no new new Seer Home studies can be scheduled or ordered. Any systems in the possession of patients who are not currently in a vEEG study using the Seer Home System will be returned to Seer Medical. Currently ongoing studies with patients that have implanted or wearable medical devices that may be susceptible to electrical interference should be halted immediately. Currently ongoing studies with patients who do not have implantable or wearable medical devices that may be susceptible to electrical interference may complete their study. Seer Home will be unavailable for an indefinite period of time, therefore any future scheduled studies must be moved to other technologies or canceled. Customers were also instructed to identify and quarantine all Seer Medical equipment and consumables that are not in use, coordinate with Seer to return the equipment, and complete and return the acknowledgement form. Seer Medical sent an updated letter to consignees via email on 08/13/2024. The letter provided updated information on the reason for recall to include how they were not compliant with Electromagnetic Compatibility (EMC) testing. Additionally, it was emphasized to customers to immediately halt any ongoing studies as patients with neurostimulators, pacemakers, cardiac defibrillators, and continuous glucose monitors are the population at greatest risk and the benefit of continuing these studies does not outweigh the risk.
Initiated
2024-08-12
Root cause
Under Investigation by firm
Distribution
Worldwide - US Nationwide distribution in the states of MN, NY, PA and the countries of Australia.
Recall number
Z-3143-2024
Recall status
Open, Classified
CDRH record ID
209565
FDA classified
2024-09-13
Recall event number
95138

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗